Eli Lilly's Insulin Glargine Injection Receives NMPA Approval in China

After 4 years of refinement, the largest IP in China's oncolytic virus field is making a significant impact. COVC 2023, the 4th Oncolytic Virus Drug Development Conference, brings together 30+ top global scientists in oncolytic virus drug development and 1000+ professionals from core oncolytic virus companies and related upstream and downstream industries. Join us in Shanghai on November 17-18. This drug is suitable for adult Type 1 and Type 2 diabetes requiring insulin treatment, as well as Type 1 diabetes in adolescents and children aged 6 years and above.